Marble Wealth LLC Buys Shares of 2,401 Labcorp Holdings Inc. $LH

Marble Wealth LLC bought a new stake in Labcorp Holdings Inc. (NYSE:LH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,401 shares of the medical research company’s stock, valued at approximately $602,000.

Other hedge funds have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new stake in Labcorp in the third quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp in the fourth quarter valued at approximately $26,000. Eagle Bay Advisors LLC bought a new position in shares of Labcorp during the fourth quarter valued at $29,000. Hantz Financial Services Inc. raised its stake in shares of Labcorp by 48.8% during the third quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 40 shares during the last quarter. Finally, Headlands Technologies LLC raised its stake in shares of Labcorp by 300.0% during the second quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 96 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction on Monday, May 11th. The shares were sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the transaction, the chief executive officer owned 107,234 shares of the company’s stock, valued at $27,291,053. This trade represents a 5.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

LH has been the subject of several analyst reports. Piper Sandler raised their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Robert W. Baird set a $334.00 price target on shares of Labcorp in a research note on Friday, May 1st. Evercore reaffirmed an “outperform” rating and set a $300.00 price target on shares of Labcorp in a research note on Wednesday, April 8th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $308.00.

Labcorp Price Performance

Shares of NYSE LH opened at $259.46 on Thursday. Labcorp Holdings Inc. has a twelve month low of $241.81 and a twelve month high of $293.72. The firm has a fifty day simple moving average of $262.86 and a 200 day simple moving average of $265.66. The company has a market capitalization of $21.28 billion, a PE ratio of 22.98, a P/E/G ratio of 1.81 and a beta of 0.90. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68.

Labcorp (NYSE:LH) last announced its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter last year, the firm earned $3.84 earnings per share. Labcorp’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, sell-side analysts forecast that Labcorp Holdings Inc. will post 17.99 EPS for the current year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.